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Abstract.  Tetranectin is a protein shared by the blood 
and the extracellular matrix.  Tetranectin is composed 
of four identical,  noncovalently bound polypeptides 
each with a molecular mass of *  21  kD.  There is 
some evidence that tetranectin may be involved in 
fibrinolysis and proteolysis during tissue remodeling, 
but its precise biological function is not known. 
Tetranectin is enriched in the cartilage of the shark, 
but the gene expression pattern in the mammalian 
skeletal system has not been determined.  In the pres- 
ent study we have examined the expression pattern and 
putative function of tetranectin  during osteogenesis. In 
the newborn mouse, strong tetranectin immunoreac- 
tivity was found in the newly formed woven bone 
around the cartilage anlage in the future bone marrow 
and along the periosteum forming the cortex. No 
tetranectin  immunoreactivity was found in the prolifer- 
ating and hypertrophic cartilage or in the surrounding 
skeletal muscle.  Using an in vitro mineralizing  sys- 
tem, we examined osteoblastic cells at different times 
during their growth and differentiation.  Tetranectin 
mRNA appeared in the cultured osteoblastic cells in 
parallel with mineralization,  in a pattern similar to 
that of bone sialoprotein,  which is regarded as one of 
the late bone differentiation markers.  To explore the 
putative biological role of tetranectin  in osteogenesis 
we established stably transfected cell lines (PC12-tet) 
overexpressing recombinant tetranectin  as evidenced by 
Northern and Western blot analysis and immunopre- 
cipitation.  Both control PC12 cells and PC12-tet cells 
injected into nude mice produced tumors containing 
bone material,  as evidenced by von Kossa staining  for 
calcium and immunostaining  with bone sialoprotein 
and alkaline phosphatase antiserum.  Nude mice 
tumors established from PC12-tet cells contained ap- 
proximately fivefold more bone material than those 
produced by the untransfected PC12 cell line or by the 
PC12 cells transfected with the expression vector with 
no insert (Mann Whitney rank sum test, p  <  0.01), 
supporting the notion that tetranectin  may play an im- 
portant direct and/or indirect role during osteogenesis. 
In conclusion,  we have established a potential role for 
tetranectin as a bone matrix protein expressed in time 
and space coincident with mineralization  in vivo and 
in vitro. 
T 
ETRANECTIN  is  a  protein  originally  purified  from 
human  plasma  that  was  found  to  be composed of 
four identical,  noncovalently bound polypeptides (14, 
16). The eDNA of human tetranectin  has been cloned (40) 
and its genomic structure revealed (3). The deduced amino 
acid sequence consists of 202 amino acids including a classi- 
cal hydrophobic 21-amino acid signal sequence. The molec- 
ular mass of the tetranectin  monomer is calculated  to be 
20,169 kilodaltons.  In accordance with the size of the eDNA, 
Northern  blot analysis  reveals  an  ~1  kb  ~ mRNA signal. 
Tetranectin shows sequence homology to asialoglycoprotein 
receptors, cartilage proteoglycan core protein and a number 
of surfactant  factors (3,  16, 40).  Tetranectin  binds to the 
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kringle  four domains  of plasminogen  (14) and apolipopro- 
tein(a) (25) and also binds to fibrin (26), calcium (14), hepa- 
rin  (14), and other sulfated polysaccharides  (13). 
Immunohistochemically,  we and others  have found  that 
tetranectin  is located in the extracellular  matrix  of human 
carcinomas,  while little  or no immunoreactivity  could be 
demonstrated in the extracellular  matrix of the correspond- 
ing normal  tissues  (11, 40). Tetranectin  mRNA is upregu- 
lated  in  the stroma  of colon cancer  (40).  The  molecular 
mechanism of this upregulated expression pattern in tumoral 
stroma,  which is reminiscent of that of tenascin (8) remains 
unknown.  The function of tetranectin  in the stroma during 
tumorigenesis  is not presently understood. 
Recently,  the primary structure of tetranectin  from reef 
shark  (Carcharhinus springeri)  cartilage  (30)  was  deter- 
mined. In shark, tetranectin  was found to be one of the main 
non-coUagenous, non-proteoglycan  components of the neu- 
rai arch cartilage.  This led us to explore the expression and 
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tem. In the present study, we have found that tetranectin gene 
expression during bone development appeared in time and 
space coincident with mineralization in vivo and in vitro. We 
established stably transfected PC12 cell lines (PC12-tet) and 
tumors generated from cells expressing tetranectin promoted 
bone formation to a  greater extent than control cell lines 
(PC12 untransfected and PC12 transfected with the expres- 
sion vector with no insert),  strongly indicating a  role for 
tetranectin during osteogenesis. 
Materials and Methods 
Cells and Culture Conditions 
A novel in vitro culture system from primary bovine osteoblast-like cells 
has recently been established in which a thick mineralized matrix is eventu- 
ally formed (42). Since the expression  patterns of some extracellular matrix 
proteins during mineraliTatjon were determined in this system (23), tetranec- 
tin expression was studied in this system. Briefly,  the osteoblast-like cells 
were isolated from 5-month-old fetal bovine long bones and cultured as de- 
scribed (23, 42). FOr the mineralization assays, cells were seeded at a den- 
sity of 300000 cells per 35-ram culture dish and grown for 3-5 d. Then 
the growth medium was exchanged with mineralization medium (designated 
day 0) which contained 10 mM beta-glycerophosphate, 15 mM Hepes, 50 
#g/ml ascorbic acid, and 0.12 ntl ITS (insulin, transferrin, and selenium; 
Sigma Chem. Co., St. Louis, MO). The cultures were maintained in miner- 
aiization medium up to 20 d. The WI-38 human embryonal lung fibroblasts 
(ATCC  CCL 75) and COS-7 (ATCC  CRL 1651) were obtained from the 
American "l~ype Culture Collection, l~ckville, MD). The CHO cells were 
kindly provided by Drs. J.  Verheijen and C. Khft, Leiden, The Nether- 
lands, and the BAE bovine endothelial cells by Dr. A. M. Mercurio (Bos- 
ton,  MA).  These cell lines were routinely maintained in DMEM  with 
Glutamax I and 4,500 mg/mi glucose, penicillin and streptomycin, and 10 % 
FCS  (growth medium).  The  PC12  cells, which are derived from a  rat 
pheochromocytoma (19), were kindly provided by Dr. A. E. Chung, (Pitts- 
burgh, PA) and maintained as described (33). 
Antibodies 
Polyclonal antibodies against tetranectin purified from human serum (code 
A371, lot 096, 0.075 mg Ig/mi) and normal rabbit serum (code 902, lot 012) 
were purchased from DAKO a/s. These antibodies have been characterized 
and used in several studies (i.e.,  10-12).  "Con  Kossa staining for calcium 
(34), polyclonal antibodies (LF-87) to bone sialoprotein (29)  kindly pro- 
vided by Dr. L. Fisher, National Institutes of Health, and antibodies to alka- 
line phosphatase (21) kindly provided by Dr. J. L. Millan (La Jolla Cancer 
Research Foundation), were applied to confirm bone formation. 
Tissues and Immunostaining 
Newborn mice (C57/BL) bred in our animal facilities were sacrificed and 
tissues collected, fixed in formalin, embedded in paraffin, cut, and pro- 
cessed for immunoperoxidase staining essentially as described (40).  Be- 
fore immunostaining, the sections were treated with 2 % H202 in methanol 
for 10 rain to abolish endogeneous peroxidase, and for the tetranectin im- 
munostainings, in addition, treated with  1 mM tranexamic acid (Sigma 
A-6516)  in 0.05 M Tris-HCl for 5 rain at room temperature. As a control 
for the tetranectin immunostaining of  the tissue sections, normal rabbit serum 
was used or competition assays were performed as follows. Tetranectin anti- 
bodies diluted 1:50 were incubated together with recombinant tetranectin 
(culture medium supernatant of PC12-tet cells) in a  1:1 ratio overnight at 
4°C, and the immunostaining was performed as described above. As a result 
only faint or no immunoreactivity was observed. When we used the untrans- 
fected PC12 cell supernatant, only a slight reduction in the intensity of the 
immunoreactivity was observed; this was most likely due to the presence 
of immunoreactive tetranectin in FBS. 
Construction of  a Tetranectin Expression Vector 
Primers were selected for PCR based on the sequence information obtained 
by eDNA cloning of human tetranectin (40) and synthesized in our labora- 
tory on an ABI model 3808 DNA synthesizer  using phosphoramidite chem- 
istry.  A PCR product containing the full-length coding sequence starting 
at the ATG (nt 94) and ending at the stop codon TAG (nt 702) was obtained, 
using 5' end sense primer with a  damp and a  Hind HI  site (Y-ATCT- 
A~oCTTA  _  CTA) and 3' end reverse complemen- 
tary primer with a clamp and a Xba I site (3'-TCTCTCTAGACTACACGAT- 
CCCGAACT).  The original tetranectin plasmid (designated TET-1) was 
used as template and conditions were as described (40). The PCR product 
was subsequently treated with restriction enzymes (Boehringer Mannheim 
Corp., Indianapolis, IN), gel-purified and subcloned into the Hind lII-Xha 
I site of the pRc/CMV expression vector (In Vitrogen, San Diego, CA), 
generating the recombinant plasmid pRc/CMV-tet. This expression vector 
contains the immediate early gene promoter of human cytomegalovirus 
(CMV) 1 for high level transcription, the polyadenylation signal and tran- 
scription termination sequences from the bovine growth hormone gene, and 
the neomycin resistance gene for selection of G-418 resistant stable cell 
lines. Highly purified plasmid was obtained as described (36). Sanger DNA 
sequencing confirmed the correct reading frame of the PCR product in the 
recombinant expression vector (pRc/CMV-tet). 
Transfection of Tetranectin 
For transient transfections subconfluent (~80%  confluent) COS-'/, CHO, 
WI-38, BAE, and PC12 cells were rinsed twice in serum-free Opti-MEM 
(GIBCO BILL, Gaithersburg, MD) and were transfected with a  2  #g of 
CsCl-handed supercoiled DNA (pRc/CMV-tet  or pRc/CMV alone as a con- 
trol) in the presence of Lipofectin Reagent according to the manufacturer's 
protocol (GIBCO BRL). After 6 h of incubation at 37°C, the DNA solution 
was removed and replaced with the growth medium for these cells, as de- 
scribed above. Cells were fixed for immunofluorescence 2 d after transfec- 
tion. For production of stably transfected cell lines, PC12 cells were used. 
The cells were seeded in 60-ram tissue culture dishes and transfected with 
5 #g DNA in the same fashion as described for transient transfections. Two 
days later, the transfectants were selected by adding G-418 sulphate (Geneti- 
cin, GIBCO BRL) at a final active concentration of 374 #g/ml. Resistant 
cells were further cloned by the limiting dilution method. Fifteen cell lines 
(PC12-tet) transfected with the pRc/CMV-tet plasmid and five cell lines 
(PC12-control) transfected with the pRc/CMV control plasmid were se- 
lected. 
RNA and Northern Blot Hybridization 
Extraction, isolation, and Northern blot analysis of the bovine osteoblast- 
like cells was performed as described previously (23). Briefly, the cells were 
rinsed in PBS, homogenized in 4 M guanidine-thiocyanate, 25 mM acetate, 
pH 5.4, and 0.12 M B-memaptoethanol and subjected to density gradient 
centrifugation. For Northern blot analysis, aliquots of 5 #g of total RNA 
for each time point were separated on 1.2%  denaturing agarose gel and 
transferred to Optibind membrane (Schleicher and Schuell, Keene, NH). 
Total RNA was isolated from the various PC12 cell lines (18) and from 
tissues of newborn mice and nude mice tumors (9) and used for Northern 
blot analysis as described (36, 40). 
SDS-PAGE and Western Blot 
Culture medium supernatant (200 ~,l/tane)  was concentrated using filters 
(Amicon, Beverly, MA). Human serum was obtained from the investigators 
and 1 #1 was applied per lane. Samples were separated on SDS-PAGE ac- 
cording to Laemmli (27)  using 14%  resolving gels and 4% stacking gels 
and  transferred to  nitrocellulose paper  (BA85, Scheicher and  Schuell). 
Western immunoblotting was performed as described (40). 
lmmunoprecipitation 
Subconfluent cells in 25-cm  2 flasks were rinsed once with PBS and labeled 
in 3 ml of methionine-free DMEM (GIBCO BRL) containing 0.292 mg/l 
L-ghtamine  (1/10 of normal  concentration),  1%  dialysed  FCS  and  50 
~.Ci/ml L-[35S]methionine (SJ 1305, Amersham Corp., Arlington Heights, 
IL) for 6 h. Tween-20, PMSF and aprotinin were added to give final concen- 
trations of 0.05 %,  1 ~  and 10 ~,g/ml, respectively, any debris removed 
by centrifugation (1,000 g, 5 min, 4°C), and the medium used directly for 
immunoprecipitation (41). Total labeled proteins were precipitated from the 
cell layer with  10%  trichloroacetic acid (TCA)  and dissolved in sample 
buffer. Labeled proteins were separated on 14% SDS-polyacrylamide gels, 
1. Abbreviations used in this paper: CMV, human cytomegalovirus; H&E, 
hematoxylin and eosin. 
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mated with En3Haneer  (New England Nuclear, Boston, MA), dried, and 
exposed to an X-Omat AR film (Kodak) at -80°C overnight  with Cronex 
intensifying  screens (New England Nuclear). 
Heterotransplantation to Nude Mice 
For a generation  of solid tumor tissue, 107 PC12, PC12-control,  or PC12- 
tet ceils were injected  subcutaneously  in the back of NMRI-nu  6-wk-old  fe- 
male nude mice (Bona mice, Bornhol~rd Breeding and Research Centre 
Ltd., RY, Denmark). Aliquots  of tumor tissues were serially transplanted 
subcutaneously  into at least five  animals  per cell line per passage. The sub- 
cutaneous tumor tissues were fixed in buffered formalin for 24 h and 
processed for embedding  into paraffin. Sections  (4 tan) were cut and stained 
with hematoxylin  and eosin (H&E) The H&E stained  sections  from tumors 
of seven  PC12 mice, seven  PC12-eontml,  and eight PC12-tet  mice (passage 
2)  were analyzed using the  Mocha Image Analysis Soflwm-e (Jandel 
Scientific,  San Rafael, CA). The following  parameters were  quautituted:  the 
average area of the tumor (in mm2), the number of sections with osteofoci 
out of total sections  analyzed,  the average size of osteofoci (in ram2), and 
the ratio of the area of osteofoci per area of tumor. Statistical  analysis  was 
performed using the chi-square  test or the Mann-Whitney  rank sum test. 
Results 
Tetranectin Gene Expression during Osteogenesis 
In Vivo 
To determine whether tetranectin synthesis was correlated 
with osteogenesis in mammals, we examined the expression 
of  tetranectin  during  bone  development using  immuno- 
histochemistry and Northern blot analysis.  Sections of a 
limb with bone formation in a newborn mouse are demon- 
strated  in Fig.  1,  A-C.  Tetranectin immunoreaetivity was 
found at locations of the newly formed woven bone.  The 
bone tissue laid down on the fibrous surface of the cartilage 
anlage (the periosteum) in the midportion of the future bone 
exhibited strong immunoreactivity with antibodies to tetra- 
nectin. Strong tetranectin immunoreactivity  was found in the 
bone laid down around the calcified cartilage cores in the 
area which becomes the future marrow space. These struc- 
tures are called the primary spongiosum or primary trabecu- 
lum and the bone material is laid down by the surrounding 
osteoblasts. No tetranectin immunoreactivity was found in 
Figure L  Tetranectin distribution during bone formation in vivo. 
Immunostaining  (A-C) with tetranectin antibodies was performed 
as described in Materials and Methods.  A longitudinal section of 
the midportion of a bone from a newborn mouse is shown.  (A) 
Columns of proliferative  chrondrocytes  (P), hypertrophic  swollen 
chrondrocytes  (H),  and their surrounding matrices do not show 
tetranectin immunoreactivity. In the zone of ossification  (O), the 
woven bone laid down by osteoblasts on the surface of a core of ear- 
tilage shows strong tetranectin immunoreactivity.  The woven bone 
laid down along cartilage cores at the periosteum, also shows in- 
tense tetranectin immunoreactivity  (arrows).  This is the future cor- 
tex of the bone. The surrounding skeletal  muscle and connective 
tissue show no tetranectin immunoreactivity.  (B) Larger magnifi- 
cation of an area with tetranectin-positive bone laid down on the 
cores of cartilage.  Again arrows point to the bone formed at the 
periosteum (C). Negative control in which the primary antibodies 
were incubated together  with recombinant tetranectin-containing 
PC12-tet supernatant. Arrow points the periosteum with no immu- 
noreactivity.  (D) Tetranectin mRNA expression  during bone for- 
mation in vivo of a newborn mouse by Northern analysis (in dupli- 
cate, lanes 1 and 2). Liver tissue mRNA isolated and analyzed in 
parallel by Northern analysis (in duplicate, lanes 3 and 4). The 1-kb 
message size of tetranectin is indicated. Control actin hybridization 
is shown below. Magnification: A, 105; Band C, 260. Bars: (A) 76 
pm; (B and C) 31 #m. 
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cartilage  extracellular  matrix.  The  surrounding  skeletal 
muscle  tissue  showed  no  immunoreactivity.  Controls  in 
which the primary antibodies were replaced with normal 
rabbit serum showed no immunoreactivity (not shown) and 
the competition assays  with recombinant tetranectin were 
also negative (Fig. 1 C). A similar pattern oftetranectin gene 
expression was observed in the rat and human developing 
bone (unpublished data). The presence of  tetranectin mRNA 
extracted from parallel newborn mouse limbs was verified 
by Northern blot analysis (Fig.  1 D). 
Tetranectin Expression  in Cultured Bone Cells 
To examine the role of tetranectin in osteogenesis, we ana- 
lyzed the  expression of tetranectin  in  an  in  vitro bovine 
mineralizing system (23,  42).  In this  system, the cultured 
cells formed multilayers and visible thick cell foci on days 
2-3 after switching growth medium to mineralizing medium 
(day 0). Mineral deposition occurred on day 4-6 and a thin 
bone  sheet  was  eventually  formed  between  days  10-20. 
Fig. 2 shows that tetranectin mRNA appeared on day 6. The 
mRNA level increased with time and maximum expression 
was found on the last day of the 20-d culture period exam- 
ined. The expression of tetranectin mRNA correlated with 
the accumulation of mineral. This expression pattern is simi- 
lar to that of bone sialoprotein, which also seems to parallel 
mineralization  and  osteoblastic  differentiation  (23).  Al- 
though  their  expression  patterns  are  similar,  tetranectin 
mRNA increased up to eightfold, while bone sialoprotein in- 
creased 140-fold.  The mRNA of another bone matrix pro- 
tein,  decorin,  increased  to  approximately  similar  extent 
(4.5-fold) as tetranectin, but it was  detectable already on 
day0. 
Expression  of  Recombinant Tetranectin 
An expression plasmid, designated pRc/CMV-tet, was con- 
strutted that contained the full-length coding sequence in- 
cluding the signal peptide. To test the ability of the construct 
to  encode recombinant tetranectin,  a  series  of cell  lines 
(COS-7,  CHO,  WI-38,  BAE,  and  PC12)  were transiently 
transfected. In all transiently transfected cell lines intense cy- 
toplasmic  immunofluorescence reactivity was  found with 
polyclonal tetranectin antibodies while cells transfected with 
the expression vector with no insert showed no immunoreac- 
tivity. No immunostalning was detected in either transfected 
or untransfected cells when normal rabbit serum replaced 
the tetranectin antiserum. Fig. 3, A and B shows an example 
of the immunostaining in the CHO cells. For a generation 
of stably transfected cell lines, we chose PC12 cells because 
this cell line had previously been successfully used for trans- 
fections with the extracellular matrix protein,  laminin B1 
chain (33).  The PC12 ceils were stably transfected with a 
recombinant plasmid pRc/CMV-tet,  and  fifteen neomycin 
resistant clones (PC12-tet) were isolated and examined for 
the expression of recombinant tetranectin by Northern and 
Western  analysis.  Untransfected  PC12  cells  and  PC12- 
control (five selected lines) served as controls. No apparent 
morphological  changes  were  observed  in  the  transfected 
cells. Northern analysis of total RNA isolated from the sta- 
bly transfected PC12-tet cells gave a strong hybridization sig- 
nal  after  an  overnight  exposure  (Fig.  3  C,  lanes  1-7), 
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Figure 2. Tetranectin mRNA at the time of mineralization in vitro. 
(a) Autoradiogram of mRNA extracted from osteoblast-like cells 
at different stages of mineralization and probed with a 32p-labeled 
human tetranectin eDNA. A photograph of the corresponding gel 
stained with ethidiurn bromide is shown below. The position of the 
18 S and 28 S ribosomal RNAs is indicated by arrows. (b) Quantita- 
tion of the relative levels of mRNA of tetranectin (-~-), alkaline 
phosphatase  (--~-), bone  sialoprotein (-<>-), and decorin  (-o-). 
The relative amount of tetranectin mRNA was determined by den- 
sitometric scanning of the autoradiogram, and compared to the rel- 
ative amounts of the other mRNAs (23) as described in Materials 
and Methods. 
whereas no signal was found in the PC12 cells (Fig. 3 C, left 
panel, lanes 8-9) or in the five PC12-control cell lines (Fig. 
3  C,  right panel,  lanes  1-5).  The amount of tetranectin 
mRNA expression varied somewhat among the tetranectin 
transfected cell lines. The size of tetranectin mRNA was ,'~1 
kb consistent with previous data (3,  40).  In Western blot 
using  culture  medium  supernatant  from  the  transfected 
PC12-tet cells, tetranectin could be demonstrated as a single 
band whereas no immunoreactivity was observed in the non- 
transfected cell lines (Fig. 3 D). The molecular mass of the 
recombinant tetranectin monomer (21 kD) was found to be 
identical to human serum tetranectin as judged by the elec- 
trophoretic mobility under reducing conditions (not shown). 
The Journal of Cell Biology, Volume  127, 1994  1770 Figure 3. Establishment of  tetranectin-producing PC12 cell lines (PCl2-tet) (.4 and B). Localization of  recombinant tetranectin  in transiently 
transfected  cells.  The CHO cells were transiently  transfeeted  with the tetranectin  eDNA expression  vector pRc/CMV-tet  (A) or with the 
control plasmid pRe/CMV (B). Cells grown in Nunc slides were briefly rinsed in 0.05 M Tris-HCl, pH 7.2, fixed in PBS-buffered formalin 
for 2 min at room temperature, and rinsed three times in 0.05 M Tris-HCl, pH 7.2. The cells were subsequently  treated with 1% NP-40 
in the Tris-HCl buffer for 1 min and with 1% Triton X-100 and 1% BSA in the Tris-HCl buffer for 2 min. Tetranectin  antibodies  were 
diluted  1:100 and normal rabbit serum 1:200 in the Tris buffer and incubated with the cells for 2 h at room temperature.  After three rinses 
in 0.05 M Tris-HCl containing 0.15 M NaCI, the cells  were incubated  with swine anti-rabbit FITC secondary antibody (F205,  DAKO) 
diluted  1:50 for 1 h at room temperature.  The cells  were rinsed  three times  in 0.05 M Tris-HCl and briefly  in distilled  water  followed 
by 99% ethanol.  Finally, the slides were air dried, mounted in glycergel (DAKO), and examined using a LSM-10 laser scanning microscope 
(Zeiss).  (C) Expression of tetranectin  mRNA by stably transfected  PC12 cell lines.  Seven independent  PC12 cell lines (PC12-tet)  stably 
transfected  with the tetranectin eDNA expression  vector, pl~/CMV-tet (lanes 1-7), and the non-transfected  PC12 ceils (lanes 8-9) were 
examined by Northern blotting (left panel).  Another Northern blot (right panel) demonstrates 5 PC12 control cell lines transfected  with 
the pRc/CMV plasmid (lanes 1-5), the non-transfected  PC12 cell line (lane 6), and one of the positive PC12-tet cell lines (lane  7).  15 #g 
of total RNA was applied  per lane.  The filter  was hybridized to the human tetraneetin  eDNA (upper panel)  and exposed  to x-ray film 
for 4 d. The filter was rehybridized  to aetin (lower panel) and exposed overnight.  The 1-kb message  size of tetranectin  is indicated.  (D) 
Western blot analysis of recombinant tetraneetin  produced by three stably transfected  PC12-tet cell lines (lanes 1-3) compared to untrans- 
fected control PC12 cells (lane 4). Culture medium supernatants  were analyzed by SDS-PAGE under reducing conditions,  transferred  to 
nitrocellulose, and immunostained with antiserum to tetranectin.  Positions  of reduced, electrophoresed, transferred,  and amido black 
stained  molecular mass standards  (M in kD) are: phosphorylase b 94,000; BSA 67,000;  ovalbumin 43,000;  carbonic anhydrase  30,000; 
soybean trypsin inhibitor 20,100; and ~-laetalbumin 14,400.  (E) Biosynthesis  of recombinant tetranectin  by transfected  cells.  Left panel 
shows aliquots of [35S]methionine-labeled  conditioned media of PC12 (lane 1) and PC12-tet (lane 2) immunoprecipitated  with tetranectin 
antibodies  or as a control with normal rabbit serum (lanes 3 and 4). The immunoprecipitates  were analyzed by SDS-PAGE under non- 
reducing conditions and fluorographed.  PC12-tet cells which had been transfected with the tetranectin  eDNA expression vector, pRc/CMV- 
tet synthesized an approximately Mr 21-kD monomer (lane 2, marked TET). The right panel shows TCA-precipitated  material  from PC12 
(lane 1 ) and PC12-tet cells (lane 2) demonstrating that the secreted  proteins  from both cell lines were labeled  to the approximate  same 
extent.  The arrows  indicate  the top of the separating  gels.  Bars,  50 tim. 
Biosynthesis was furthermore documented by immunopre- 
cipitation of L-[35S]methionine metabolically labeled PC12- 
tet cell culture supernatants  with tetranectin antiserum and 
is shown in Fig. 3 E. A single strong 21-kD band was precipi- 
tated from the medium of PC12-tet cells (lane 2) whereas the 
medium of  untransfected cells (PC12) showed no bands (lane 
1).  Control nonimmune  serum did not precipitate  any la- 
beled proteins  (lanes  3  and  4).  No other molecular mass 
bands were observed even after prolonged exposure neither 
under  nonreducing  nor  reducing  conditions  (not  shown). 
These data show that by SDS-PAGE recombinant tetranectin 
was produced by the PC12-tet cells as a 21-kD monomer as 
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and previous Northern blot analysis (3, 40). Thus, the 21-kD 
recombinant tetranectin monomer synthesized by PC12-tet 
cells appeared to be identical to plasma tetranectin. 
Increased Bone Formation in Tumors Produced by 
Cells Transfected with Tetranectin 
Nude mice were injected subcutaneously with PC12, PC12- 
control, and PC12-tet cell lines, and all produced tumors to 
the same extent. Northern blot analysis of RNA extracted 
from tumors showed that tetranectin mRNA was present in 
tumors produced by PC12-tet cells but not detectable under 
the same conditions in tumors produced by the PC12 cells 
(Fig. 4 A) or by the PC12-control (not shown). Paraffin sec- 
tions from tumors were examined at the light microscopic 
level.  H&E-stained  sections of tumors  from both  PC12, 
PC12-control, and PC12-tet cells contained foci of bone ma- 
terial by morphological criteria (Fig. 4, B and C). In parallel 
sections, the bone foci stained positively for calcium by the 
von Kossa method (Fig. 4 D) and with antibodies to alkaline 
phosphatase and bone sialoprotein (not shown),  verifying 
that the material was bone. The bone material stained posi- 
tively with antibodies for tetranectin (not shown). The tumor 
nodules were surrounded by dense fibrous tissue, and iso- 
lated strands of skeletal muscle were often seen. Bone and 
cartilage were usually located at the periphery of the tumor 
nodules, interposed between fibrous tissue and PC12 tumor 
tissue. Much less bone and cartilage were located in the more 
central part of the tumor. This morphologic pattern was as 
described previously for some epithelial cell lines inducing 
bone formation when injected into nude mice (1, 43).  By 
morphological examination tumors  produced by PC12-tet 
cells appeared to contain significantly more bone material 
than those produced by the untransfected PC12 cells or by 
PC12-control cells, by several parameters that were quanti- 
tated by Mocha Image Analysis Software and LSM laserscan 
microscopy (Table I). First, among 121  sections examined 
of  control mice injected with PC12 or PC12-control ceils, ap- 
proximately half of  them had osteofoci, while all sections ex- 
amined of mice injected with PC12-tet cells had osteofoci; 
and this difference was  statistically significant (chi-square 
test; p  <  0.0001).  Second, the average size of osteofoci in 
tumors generated by PC12-tet cell was double that of  the con- 
trol tumors (Mann-Whitney rank sum test; p < 0.05). Third, 
the area  (measured in mm  2) of bone formation in tumors 
generated by the tetranectin-transfected cells was approxi- 
mately five times larger than that of  the control cells. Statisti- 
cal  analysis  demonstrated  that  the  difference was  highly 
significant (Mann-Whitney rank sum test; p  <  0.01). These 
findings, together with the appearance of tetranectin protein 
and  mRNA  during  bone formation in  vivo and  in  vitro, 
strongly indicate that tetranectin plays a role in osteogenesis. 
Discussion 
The data presented in this paper suggest a previously unex- 
pected role for tetranectin in osteogenesis. Tumors produced 
in nude mice by PC12 cells transfected with a  tetranectin 
cDNA expression vector contained approximately five times 
as  much bone material compared to tumors produced by 
non-transfected control cells or PC12 cells transfected with 
the expression vector with no insert. Furthermore, during 
Figure 4. Nude mice tumors with bone formation. (A) Expression 
of  tetranectin mRNA in nude mice tumors. Total RNA (15 #g/lane) 
isolated from nude mice tumors of PCl2 untransfected control cells 
(lanes  1  and 2)  and PC12-tet cells  transfected with  tetranectin 
cDNA expression vector (lanes 3 and 4) were analyzed by Northern 
blotting. The filter was hybridized to the human tetranectin cDNA 
(upper  panel) and exposed to x-ray films for 3 d. The filter was re- 
hybridized to actin (lower  panel) and exposed overnight. The 1-kb 
message size of tetranectin is indicated. (B) Morphologic analysis 
of H&E stained paraffin sections of nude mice tumors generated 
by PC12-tet cells compared to the untransfected PC12 cells, shown 
in C. Bone material is the homogeneous, acellular material. In par- 
allel sections of the PC12-tet tumors, yon Kossa staining for cal- 
cium verifies the presence of bone, shown in D. Symbols on the 
figures indicate: T, tumor; B, bone; C, connective tissue. Magni- 
fications: (B and C) 340; D,  160. Bars: (B and C) 24 #m; (D), 
50 ~m. 
mineralization in vitro, the expression of tetranectin mRNA 
was induced and increased during the course of mineraliza- 
tion.  This observation is  consistent with  the  finding that 
tetranectin immunoreactivity and  mRNA  are  strongly ex- 
The Journal of Cell Biology,  Volume 127, 1994  1772 Table L  Quantitation  of Bone Material in Nude Mice Tumors Generated by Injection  of PC12-tet Cells Compared to Two 
Sets of Controls,  Untransfected  PC12 Cells and PC12 Cells  Transfected  with the Expression  Vector with No Insert 
Number of sections 
Average mm  2  with osteofoci out  Average mm  2 
Number of  of tumor  of total sections  Average  size of  osteofoci per 
cases  specimen  analyzed  osteofoci  in mm  2  ram  ~ tumor 
PC12  controls*  14  14.24  5:4.37  51/121  1.01  5:0.89  0.03  5:0.03 
PC12-tet  7  14.28  5:2.99  25/25~  2.27  5:  1.67§  0.16  5:0.1411 
* The controls include untransfected PC12 cells and PC12 cells transfeeted with the expression vector with no insert. There were no differences between the two 
types of control cell lines and they were therefore  combined far statistical analysis. 
¢ All sections from tumors generated by PC 12-tet cells contained osteofoci whereas only approximately half of the sections from tumors generated by control PC 12 
cells contained osteofoci. Statistical analysis using the chi-square test showed that the difference is highly statistically significant, chi-square = 27.78 with 1 degree 
of freedom; p  < 0.0001. 
§ The size of osteofoci in tumors generated by PCl2-tet cells is significantly larger than the size of osteofoci in tumors generated by PC12 control cells. Statistical 
analysis was performed  using Mann-Whitney rank sum test;  19 degrees of freedom;  t  =  2.22; p  <  0.05.  Values are the mean  +  SEM. 
II The area of osteofoci in tumors generated by PC12-tet cells is significantly larger than the area of osteofoci in tumors generated by PCI2 control cells. Statistical 
analysis was performed using Mann-Whitney rank sum test; 20 degrees of freedom; t  =  3.008; p  <  0.01.  Values are the mean  +  SEM. 
pressed at sites of ongoing osteogenesis during limb develop- 
merit in the newborn mice. 
Previous studies have shown that the tetranectin polypep- 
tide and its mRNA have a wide tissue distribution (3, 10, 11, 
12, 40). High tetranectin mRNA levels were found in several 
human normal tissues,  i.e.,  placenta,  heart,  spleen,  and 
lung, but little was detected in the liver or in the kidney (3, 
40). Tetranectin is present in normal human plasma at a con- 
centration of '~15 mg/1 (14), and the plasma concentration 
of tetranectin is reduced in patients with various malignan- 
cies (22, 24).  Neame et al. (30) found tetranectin to be an 
abundant component of shark cartilage. The role of  tetranec- 
tin during bone formation in the mammals was explored in 
the present  study. We found that tetranectin mRNA was 
expressed in newborn limbs and that the polypeptide was 
deposited in the newly formed woven bone. The in vitro ex- 
periments confirmed that the osteoblastic cells transcribe 
tetranectin mRNA. 
The biosynthesis and biochemical processing of tetranec- 
tin has not been unequivocally determined. This has been 
hampered in part by the fact that little tetranectin production 
can be detected in cultured cell lines at either the protein or 
mRNA level. We were however able to show the biosynthesis 
of tetranectin using PC12-tet cells (Fig. 3). Previous studies 
using tetranectin polyclonal antiserum in Western blots have 
revealed an additional 95-100-kD immunoreactive band in 
some cultured cells and in leukocytes (6, 15). One suggestion 
was that the 95-100-kD band might be a tetranectin-related 
protein species. However, eDNA cloning and Northern blot 
analysis demonstrated a  1-kb mRNA of tetranectin (3, 40), 
strongly arguing against the existence of a precursor-product 
relationship. The data compiled in the present study shows 
that recombinant tetranectin produced by the PC12-tet cells 
is not incorporated into a 95-100-kD species, and therefore 
does not support the hypothesis that tetranectin complexes 
with another gene product. 
During  the  process  of osteogenesis,  the  expression  of 
a  number  of noncollagenous  proteins,  such  as  alkaline 
phosphatase, osteopontin, osteonectin/SPARC, bone sialo- 
protein,  osteocaicin,  matrix  protein  Gla,  and  the  small 
proteoglycans decorin  and biglycan,  varies  spatially and 
temporally (2, 4, 5, 17, 20, 28, 35, 39).  We now add to this 
list another protein present in the bone matrix, tetranectin. 
In the long bone of the newborn mouse, tetranectin immuno- 
reactivity was found to be confined to the newly formed 
woven bone  in the periosteum and the primary spongio- 
steum, suggesting that tetranectin is a rather late differentia- 
tion marker protein. No apparent tetranectin immunoreac- 
tivity was observed in the cartilage in the same sections. 
Likewise, Neame et al.  (30)  failed to detect tetranectin in 
mammalian cartilage. It should be noted however,  that we 
have not yet examined tetranectin during embryogenesis and 
thus cannot exclude that tetranectin could be present in the 
cartilage of the developing fetus. Osteonectin/SPARC was 
found to be present in the hypertrophic zone of fetal mouse 
bone but absent at this location in the newborn mouse (35). 
Another aspect that remains to be explored is whether the 
gene expression pattern of tetranectin as assessed by in situ 
hybridization corresponds with the matrix deposition deter- 
mined by immunohistochemicai methods. 
To specify the expression of tetranectin by osteoblasts as 
a function of time, we used an in vitro system (42) in which 
the differentiation of cultured bovine osteoblasts, proteins 
such as decorin and osteonectin/SPARC are induced early, 
while others such as bone sialoprotein are expressed at later 
stages (23).  In this assay tetranectin was first detected 6 d 
after the switch to mineralization medium, at the stage when 
mineralizing nodules have started to form. At this stage the 
alkaline phosphatase mRNA expression was highest. The 
time course of tetranectin mRNA induction was similar to 
that of bone  sialoprotein,  which  is  thought to be  a  late 
differentiation marker (5,  17, 23),  consistent with our im- 
munolocalization results. In studies using primary cultures 
of normal diploid rat osteoblasts, levels of  matrix Gla protein 
were present during the proliferative period and increased 
during the period of matrix formation (2, 31). The expres- 
sion of osteocalcin, on the other hand, was initiated at the 
onset of mineralization (2, 31), which is comparable to the 
expression pattern of tetranectin observed in our in vitro as- 
say system. Thus, the onset and pattern of tetranectin gene 
expression most closely resembles that of bone siaioprotein 
and osteocalcin, except its magnitude of enhancement. Since 
tetranectin mRNA levels remained high at the later stage of 
mineralization, tetranectin may not only be involved in the 
ongoing process of mineralization, but may have other func- 
tions in mature osteoblasts. 
The mechanisms of bone formation have been explored 
using a variety of in vivo experimental systems (38). Some 
epithelial cell lines induce bone formation when implanted 
into connective tissue of nude mice (1, 43) and this was found 
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alkaline phosphatase-enriched matrix vesicles (7).  During 
the process of bone induction at ectopic sites, mesenchymal 
ceils migrate to the "implant" and differentiate into chondro- 
cytes, which then synthesize and calcify their matrix. The 
calcified cartilage is vascularized and bone forms on the car- 
tilage scaffold (38). Bone formation in general is attributable 
to a large number of bone morphogenetic proteins and bone- 
derived growth factors that may act in both a paracrine and 
autocrine fashion (17, 38). In the present study we used PC12 
cells that induce and support osteogenesis after their injec- 
tion  into  nude  mice  (our  unpublished  results),  and  we 
showed that the degree of bone induction was augmented by 
the overexpression of tetranectin. The role that tetranectin 
may play in osteogenesis is unknown, but it may relate to its 
ability to bind to plasminogen and to stimulate plasminogen 
activation by tissue-type plasminogen activator under certain 
conditions (14) and thereby contribute to the regulation of 
tissue formation and remodeling. Tetranectin binds to cal- 
cium and heparin (14) and thus could be an integral compo- 
nent of the bone matrix, which contains calcium and pro- 
teoglycans (17). In addition to tetranectin,  other proteins 
such as thrombospondin and fibronectin are shared by the 
blood and the extracellular matrix (37). Finally, it is interest- 
ing to speculate that tetranectin interacts with growth fac- 
tors, as has been shown with the other bone matrix proteins 
osteonectin/SPARC (32) and decorin (44). 
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